HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide

Multiple myeloma (MM) is a hematological malignancy of plasma cells in the bone marrow. Despite multiple treatment options, MM is inevitably associated with drug resistance and poor outcomes. Histone deacetylase inhibitors (HDACi's) are promising novel chemotherapeutics undergoing evaluation in...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Canella, Alessandro, Nieves, Hector Cordero, Sborov, Douglas W., Cascione, Luciano, Radomska, Hanna S., Smith, Emily, Stiff, Andrew, Consiglio, Jessica, Caserta, Enrico, Rizzotto, Lara, Zanesi, Nicola, Stefano, Volinia, Kaur, Balveen, Mo, Xiaokui, Byrd, John C., Efebera, Yvonne A., Hofmeister, Craig C., Pichiorri, Flavia
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2015
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4741593/
https://ncbi.nlm.nih.gov/pubmed/26429859
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi